Last Updated:
4:10 pm
Monday, November 3, 2025
Dimerix Ltd. engages in the investment of the research and development of biopharmaceutical drugs. It focuses on the development of Dimerix DMX-200 drug candidate in both renal and respiratory indications and the development of Dimerix DMX-700 pre-clinical asset in Chronic Obstructive Pulmonary Disease. The company was founded on May 13, 1975 and is headquartered in Melbourne, Australia.
asx-dxb
Market Cap
AU$329.27M
Volume
402992
Open
0.50
AU$
High
0.51
AU$
Low
0.49
AU$
Shares On Issue
599M
52 Week Low
0.3
AU$
52 Week High
0.785
AU$
Website
www.dimerix.com
Consensus
N/A
Last Report Date
N/A
Next Report Date
N/A
Next Dividend date
N/A
Short Sell
N/A
Short Sell Change (1mth)
N/A
Free ASX Market Outlook & Top Stock Picks for 2025
Instantly access our exclusive report and see which stocks our analysts are backing for growth this year.
Download Free Report
Related
Our friendly team is here to help.
If you have any questions or feedback about our service, please feel free to contact us.
© Australian Stock Report Pty Ltd. All rights reserved